No article text was recorded for this version.
targeted therapy limitations
Version 2 of 253 papers54 conceptsfrozen 2026-10-04
Papers in this version
- Blog: The inhibitory effect and targets of CRM197 on tumor growth in arsenic-transformed cells and lung cancer cells
- Blog: Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer
- Blog: Synergistic gambogic acid/Ga³⁺ remodels the immunosuppressive tumor microenvironment to enhance triple-negative breast cancer therapy
- Blog: Neuroendocrine Carcinoma of the Sigmoid Colon with Liver Metastases: A Case Report
- Blog: Current Understanding of Carotid Body Paraganglioma Management
- Blog: Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model
- Blog: Operative treatment of cystic prolactinomas: a retrospective study
- Blog: Adverse events of bevacizumab for triple negative breast cancer and HER-2 negative metastatic breast cancer: A meta-analysis
- Blog: An integrated bioinformatics analysis to dissect kinase dependency in triple negative breast cancer
- Blog: Preparation and functional validation of rabbit anti-canine CD3ε monoclonal antibody
- Blog: CDK16 promotes the progression and metastasis of triple-negative breast cancer by phosphorylating PRC1
- Blog: HPV Infection and EGFR Activation/Alteration in HIV-Infected East African Patients with Conjunctival Carcinoma
- Blog: Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort
- Blog: Neural Functions Play Different Roles in Triple Negative Breast Cancer (TNBC) and non-TNBC
- Blog: T-cadherin is associated with prognosis in triple-negative breast cancer
- Blog: AXL knockdown gene signature reveals a drug repurposing opportunity for a class of antipsychotics to reduce growth and metastasis of triple-negative breast cancer
- Blog: WXJ-202, a novel Ribociclib derivative, exerts antitumor effects against breast cancer through CDK4/6
- Blog: Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells
- Blog: GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer
- Blog: Downregulation of complement factor H attenuates the stemness of MDA‑MB‑231 breast cancer cells via modulation of the ERK and p38 signaling pathways
- Blog: BTK inhibitor combined with anti‑PD‑1 monoclonal antibody for the treatment of CD20‑negative primary central nervous system lymphoma: A case report
- Blog: Targeted Inhibition of miR-221/222 Promotes Cell Sensitivity to Cisplatin in Triple-Negative Breast Cancer MDA-MB-231 Cells
- Blog: Prospects of Immunotherapy for Triple-Negative Breast Cancer
- Blog: Histological Analysis of γδ T Lymphocytes Infiltrating Human Triple-Negative Breast Carcinomas
- Blog: PWRN1 low expression facilitates cancer progression and is an unfavorable prognosis factor in breast cancer
- Blog: The LncRNA RMST-miR-4295-ITPR1 axis: a key mechanism in regulating autophagy in triple-negative breast cancer cells
- Blog: Ferroptosis: the emerging player in remodeling triple-negative breast cancer
- Blog: Belinostat exerts antitumor cytotoxicity through the ubiquitin‐proteasome pathway in lung squamous cell carcinoma
- Blog: LIMCH1 inhibits antitumor immunity by upregulating PDL1 in triple-negative breast cancer
- Blog: A pyroptosis-associated gene risk model for predicting the prognosis of triple-negative breast cancer
- Blog: Periostin drives extracellular matrix degradation, stemness, and chemoresistance by activating the MAPK/ERK signaling pathway in triple–negative breast cancer cells
- Blog: Stathmin 1 expression in neuroendocrine and proliferating prostate cancer
- Blog: Characterization of Exosome-Related Gene Risk Model to Evaluate the Tumor Immune Microenvironment and Predict Prognosis in Triple-Negative Breast Cancer
- Blog: SLC7A5: A Potential Molecular Target for the Diagnosis and Treatment of TNBC
- Blog: UNBS5162 induces growth inhibition and apoptosis via inhibiting PI3K/AKT/mTOR pathway in triple negative breast cancer MDA‑MB‑231 cells
- Blog: Evaluation of the efficacy of PD‑1/PD‑L1 inhibitor plus bevacizumab and chemotherapy for the treatment of patients with driver gene‑negative advanced‑stage lung adenocarcinoma: A retrospective cohort study
- Blog: Metabolomic machine learning-based model predicts efficacy of chemoimmunotherapy for advanced lung squamous cell carcinoma
- Blog: Photothermal therapeutic effects and biosafety of a carbon nanoparticles–Fe(<scp>ii</scp>) complex for triple-negative breast cancer
- Blog: Mitochondrial Protein UCP1 Inhibits the Malignant Behaviors of Triple-negative Breast Cancer through Activation of Mitophagy and Pyroptosis
- Blog: Proteogenomic characterization identifies clinical subgroups in EGFR and ALK wild-type never-smoker lung adenocarcinoma
- Blog: Development of a Bioluminescent BRCA1-Deficient Xenograft Model of Disseminated, High-Grade Serous Ovarian Cancer
- Blog: RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation
- Blog: COP1, the negative regulator of ETV1, influences prognosis in triple-negative breast cancer
- Blog: Silencing of PGK1 Promotes Sensitivity to Paclitaxel Treatment by Upregulating XAF1-Mediated Apoptosis in Triple-Negative Breast Cancer
- Blog: Recurrent gain-of-function USP8 mutations in Cushing's disease
- Blog: NIR diagnostic imaging of triple-negative breast cancer and its lymph node metastasis for high-efficiency hypoxia-activated multimodal therapy
- Blog: The circRNA circSEPT9 mediated by E2F1 and EIF4A3 facilitates the carcinogenesis and development of triple-negative breast cancer
- Blog: AI-powered omics-based drug pair discovery for pyroptosis therapy targeting triple-negative breast cancer
- Blog: Proteomic characterisation of triple negative breast cancer cells following CDK4/6 inhibition
- Blog: Bioinformatics driven discovery of small molecule compounds that modulate the FOXM1 and PPARA pathway activities in breast cancer
- Blog: Aquaporin 1 knockdown inhibits triple‑negative breast cancer cell proliferation and invasion <i>in vitro</i> and <i>in vivo</i>
- Blog: Clinical Implications of iNOS Levels in Triple-Negative Breast Cancer Responding to Neoadjuvant Chemotherapy
- Blog: Melanophilin inhibit the growth and lymph node metastasis of triple negative breast cancer via the NONO-SPHK1-S1P axis
History & citation
Current · Permanent link
Cite this direction
Latest version (a living page):
@misc{lacuna_targeted_therapy_limitations_44624635,
title = {targeted therapy limitations},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/targeted-therapy-limitations/rdr_44624635eb6645929a355341f3583a6a},
note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-21},
}This exact version (version 2, frozen text):
@misc{lacuna_targeted_therapy_limitations_44624635_v2,
title = {targeted therapy limitations},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/targeted-therapy-limitations/rdr_44624635eb6645929a355341f3583a6a/v/2},
note = {Version 2, frozen 2026-10-04. Accessed 2026-11-21},
}